Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredient Ixekizumab, Atc L04Ac13 (Obo) For The Period July 1St, 2024 - June 30Th, 2026

  Address - Germany

  Contact details - 565656565

  Tender notice no. - 76454545

  GT Ref Id - 81836335

  Document Type - Tender Notices

Description - Description: Section 130a paragraph 8 SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount agreements for the medicines to be supplied at the expense of the statutory health insurance companies. With re gard to the relevant legal regulations for the awarding of public contracts, a regular process of active ingredient-related, formal award procedures takes place in accordance with the regulations of Part 4 of the GWB by DAK-Gesundheit. For medicines to be specified by the bidder in Annex 2 to the contract in relation to the above. Active ingredient, Ixekizumab, ATC L04AC13, DAK-Gesundheit intends to conclude drug discount agreements with as many

Gt Ref Id - 81836335

Deadline - May 05, 2026